The ZEUS trial, which is evaluating interleukin-6 inhibition with ziltivekimab in patients with cardiovascular disease, chronic kidney disease, and systemic inflammation, is highly anticipated for its potential to reshape cardiovascular risk management. The gene discussed is IL6; the disease is chronic kidney disease.